SCHEMBL33528430

SCHEMBL33528430

CC(C)(C)OC(=O)N(F)[C@@](F)(Cc1ccccc1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.41
AKT1 P31749 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HIF1A Q16665 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA7 P43166 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CTSS P25774 3/20 0.38
CTSK P43235 2/20 0.38
IDO1 P14902 1/20 0.37
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
HTR2C P28335 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28369074 0.76 SMN1; SMN2 (0.50) L3MBTL1SMN1; SMN2HIF1A
SCHEMBL7316714 0.76 SMN1; SMN2 (0.50) L3MBTL1SMN1; SMN2HIF1A
SCHEMBL31522777 0.74 L3MBTL1 (0.42) L3MBTL1AKT1SMN1; SMN2HIF1APPARG
SCHEMBL8366831 0.74 L3MBTL1 (0.42) L3MBTL1AKT1SMN1; SMN2HIF1APPARG
SCHEMBL25182230 0.74 L3MBTL1 (0.42) L3MBTL1AKT1SMN1; SMN2HIF1APPARG
SCHEMBL18248193 0.73 L3MBTL1 (0.38) L3MBTL1AKT1SMN1; SMN2HIF1APPARG
SCHEMBL30887346 0.73 SMN1; SMN2 (0.50) SMN1; SMN2HIF1APPARGPPARA
SCHEMBL3736878 0.73 SMN1; SMN2 (0.50) SMN1; SMN2HIF1APPARGPPARA
SCHEMBL29112713 0.73 SMN1; SMN2 (0.50) SMN1; SMN2HIF1APPARGPPARA
SCHEMBL17559223 0.72 AKT1 (0.40) L3MBTL1AKT1SMN1; SMN2HIF1APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091118-A1 Methods for Preparation and Use of BacPROTACs for Targeted Protein Degradation in Mycobacteria and Other Bacteria WASHINGTON UNIVERSITY (US) 2026-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091118-A1 Methods for Preparation and Use of BacPROTACs for Targeted Protein Degradation in Mycobacteria and Other Bacteria CLPP, DNPEP, NPEPPS L3MBTL1 2713/4885AKT1 4502/4885SMN1; SMN2 3630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.